Mutations of the p53 tumour-suppressor gene are the most common genetic alteration observed in human tumours including the common adult epithelial malignancies of breast (Prosser et al., 1990) , colon (Baker et al., 1989) and lung (Takahashi et al., 1989) . Originally identified through its association with SV40 large T antigen in virus-transformed cells (Lane & Crawford, 1979) and as an overexpressed antigen in chemically transformed sarcoma cells (DeLeo et al., 1979) , p53 was initially classified as an oncogene because of its ability to transform cells in culture (Eliyahu et al., 1984; Jenkins et al., 1984) . Subsequent analysis associated this property with a mutant p53 clone (Hinds et al., 1989) , and evidence of deletion of both alleles of the gene in erythroleukaemia cell lines (Mowat et al., 1985) , loss of heterozygosity at the p53 locus in a variety of tumours and evidence of a tumour-suppressive function for wild-type p53 (Chen et al., 1990 ) established p53 as a tumour-suppressor gene.
The majority of p53 mutations are missense point mutations (Hollstein et al., 1991; Levine et al., 1991) clustered in the most highly conserved domains of the gene spanned by exons 4-9 (Soussi et al., 1990) . Missense mutations frequeritly induce changes that prolong the half-life of the p53 protein (Finlay et al., 1988) , and as a result mutant p53, unlike wild-type p53, accumulates in tumour cells to levels detectable by immunohistochemical methods. Elevated levels of p53 have been detected immunohistochemically in several tumour types, and when p53 has been sequenced in these tumours missense mutations are usually found (Bartek et al., 1990; Rodrigues et al., 1990) .
The MDM2 gene, which encodes a p53-associated protein, was first identified as a dominantly transforming oncogene in a tumorigenic mouse fibroblast cell line containing doubleminute chromosomes, the cytogenic hallmark of gene amplification (Fakharzadeh et al., 1991) . Following this, the rat homologue of the MDM2 gene was subsequently found to form a complex with the p53 gene, to inhibit p53-mediated transactivation (Momand et al., 1992) , and amplification of (Oliner et al., 1992) . A candidate suppressor gene, DCC (deleted in colorectal carcinoma), has recently been cloned by mapping a region of chromosome 18q that frequently shows allelic deletion in sporadic colorectal carcinomas (Fearon et al., 1990) . In keeping with the idea that DCC is a suppressor gene, injection of anti-sense RNA to the DCC gene results in the transformation of Rat-I fibroblasts (Narayanan et al., 1992) .
We have previously described mutations of the p53 and RBI tumour-suppressor genes in human sarcomas (Stratton et al., 1989 (Stratton et al., , 1990 . Abnormalities of the p53 gene were most frequently found in leiomyosarcomas and rhabdomyosarcomas, but only a limited series of primary leiomyosarcomas were examined and only a single exon, exon 5, of the p53 gene was screened for point mutations in these tumours. We have extended these studies by systematically screening a series of primary leiomyosarcomas for abnormalities of p53 using (i) immunohistochemical staining to screen for p53 overexpression, (ii) SSCP analysis to screen for point mutations in exons 4-9 of the p53 gene and (iii) direct sequencing analysis to define point mutations. In (Garvin et al., 1986) and MNNG-HOS (Rhim et al., 1975) (Steffen & Weinberg, 1978) . DNA was digested with a 3-to 5-fold excess of an appropriate restriction enzyme, subjected to electrophoresis in 0.8% agarose gels and transferred to Hybond-N filters (Amersham) according to the manufacturer's instructions. Filters were hybridised according to published protocols (Church & Gilbert, 1984 ) to x-32P-labelled probes prepared using random oligonucleotide primers (Feinberg & Vogelstein, 1983) .
Rearrangement of the DCC gene was analysed using two partial cDNA probes, pDCC1.0 and pDCC1.65 (Fearon et al., 1990) . Amplification of the MDM2 gene was assessed using a 1.5 kb MDM2 probe prepared by PCR amplification of reverse-transcribed normal fibroblast RNA using the following primers: GGGAGCTCCTCGCCACCATGGTGAG-GAGCAGGCAAATG and GGGGTACCCTCATAGACA-GGTCAACTAGGGG. The PCR product was subcloned into the pBluescript vector and characterised by sequencing of its entire length. Following hybridisation to the MDM2 probe, blots were stripped by immersion in 0.1% sodium dodecyl sulphate (SDS) at 95°C and reprobed with pDCCI.0 as a control to correct for differences between tumour samples in DNA loading and Southern transfer (Oliner et al., 1992) . The degree of amplification was quantified with a Joyce Loebel Chromoscan 3 scanning densitometer, using absorbance at 530 nm.
Evidence for DNA insertion within a 0.17 kb XbaIEcoO109 fragment of the DCC gene (Fearon et al., 1990) was examined by probing Southern blots of EcoRI-EcoOI09-digested DNA of peripheral blood and tumour pairs with a probe that detects a single 600 bp EcoRI-EcoO109 fragment that spans the 0.17 kb XbaI-EcoO 109 fragment. The probe was made by PCR amplification of normal DNA using the following primers: GGAGGAAGCAACTTACGGAT and TCTAGAGGGAAAATGTCATC.
Loss of heterozygosity on chromosome 18q was assessed using the following probes: pERT25 (D18Sl1), which detects a VNTR at 18q23, and OLVIIEIO (D18S8) (Marlhens et al., 1987) , SAM1.1 and JOSH4.4, which are polymorphic probes from within the DCC gene. pERT25 was obtained from the ATCC.
PCR amplification The p53 and DCC genes were amplified from extracted cellular DNA by 30 cycles of the polymerase chain reaction (Saiki et al., 1988) Analysis ofgene expression using PCR RNA was extracted from subconfluent cultures of cell lines and normal human fibroblasts as previously described (Favaloro et al., 1980) . A 0.2 ytg aliquot of total RNA was reverse transcribed with random hexamer primers (Noonan & Roninson, 1988) 
Immunohistochemistry
The mouse monoclonal antibody p53-DO7, which recognises both mutant and wild-type human p53, was used to stain both frozen and paraffin-embedded tumour material using a standard peroxidase-conjugated streptavidin-biotin method (ABC). Control slides omitting the first antibody were negative in all cases. The degree of immunostaining was graded as follows: (+), <10% nuclei staining intensely; (+ +), 10-50% nuclei staining intensely; (+++ +), >50% nuclei staining intensely.
Statistical analyses Differences in overall survival and disease-free survival between patients with or without p53/MDM2 mutant tumours were tested using log-rank tests and were plotted according to the Kaplan-Meier method. The association between p53/MDM2 mutation and clinical variables such as age, tumour site, American Joint Committee (AJC) clinical stage (Russell et al., 1977) and histological grade were assessed using appropriate chi-square tests. The date of the definitive operative procedure was taken as the date of diagnosis.
Results
Overexpression ofp53 in leiomyosarcomas Using the monoclonal antibody p53-DO7, immunostaining demonstrated overexpression of the p53 protein in five tumours (Table I, Figure 1) .
Abnormalities of the p53 gene detected by SSCP analysis and DNA sequencing SSCP was used to screen 29 leiomyosarcomas for point mutations in exons 4-9 of the p53 gene. SSCP analysis can detect point mutations in PCR-amplified segments of DNA by virtue of the fact that the rate at which PCR-amplified segments of single-stranded DNA migrate in non-denaturing gels depends upon both the strand size and base composition of the PCR product (Orita et al., 1989) . Abnormal SSCP band patterns were detected in five tumours (Table I, exon 7. In addition, we have previously shown that two of the tumours in this study group had undergone homozygous deletion of the p53 gene (Stratton et al., 1990) . Taken together, these results show that 8/29 (28%) of the leiomyosarcomas in our study group possessed missense point mutations or had undergone deletion of the p53 gene.
These results are summarised in Figure  4 ). Although densitometry may be unable to measure amplification of this degree accurately, the levels of MDM2 amplification in these tumours are clearly significant. Years since diagnosis Figure 5 Kaplan-Meier actuarial survival curves for leiomyosarcoma patients in this study. a, Overall survival by clinicopathological stage. b, Overall survival by p53 mutation. c, Overall survival by p53 and MDM2 mutation.
Correlation ofp53/MDM2 mutations with clinical data Of the 29 primary leiomyosarcomas analysed in this study, 25 arose in soft tissue, two arose in the bladder and two were uterine in origin. Analyses correlating AJC clinical staging and p53/MDM2 mutation were restricted to tumours arising in the retroperitoneum, the mesentery and the limb. Rare tumours arising in the uterus and bladder were omitted from this analysis. STS38 (which possesses an intronic mutation) was considered to possess wild-type p53 for the purposes of the molecular and clinical correlation analyses. p53 mutation alone was not significantly associated with patient age, site of primary tumour, tumour stage, overall survival or disease-free survival. There was, however, some evidence that p53 mutation alone was associated with a more advanced tumour stage (P = 0.08). When p53 mutations and MDM2 amplification were considered together, the presence of either a p53 mutation or amplification of the MDM2 gene was significantly associated with advanced tumour stage (P = 0.03). The survival curves for patients with mutant (p53 or MDM2) and non-mutant tumours were not significantly different. The results are summarised in Table II and Figure   5 .
Abnormalities of the DCC gene A number of approaches have been used to screen a variety of sarcomas, including liposarcomas, malignant fibrous histiocytomas, leiomyosarcomas, malignant peripheral nerve sheath tumours, rhabdomyosarcomas, synovial sarcomas and fibrosarcomas, for abnormalities in the DCC gene. Analysis of DCC expression by PCR amplification of cDNA revealed DCC expression in only two of the eight sarcoma cell lines examined, HT1080 and A673 (Figure 6a ).
Southern analysis of 78 primary sarcomas and 12 sarcoma cell lines, using the probes pDCCl.0 and pDCCI.6, identified a single cell line, SK-UT-1, with an abnormal band pattern in both HindIII-and EcoRI-digested DNA (results not shown). Of 12 mutations originally observed in the DCC gene, ten involved DNA insertion within a 600 bp EcoRIEcoOl09 fragment of the gene. This DNA insertion has proved to be unclonable (Fearon et al., 1990) . Southern analysis of EcoRI-EcoOI09 double-digested SK-UT-1 DNA suggests that the abnormal band pattern seen in this cell represents such an insertion mutation (Figure 6b) .
Finally, analysis of loss of heterozygosity on 18q revealed an allelic loss rate in sarcomas of only 10% (3/29 informative blood-tumour pairs). we have already demonstrated that in some sarcomas the coincident loss of both the RBI and the p53 tumour-suppressor genes appears important for the development of the fully malignant phenotype (Stratton et al., 1990) . The association between p53/MDM2 mutation and advanced clinicopathological stage suggests that p53 mutation may be a late event in sarcoma development, as observed in colorectal tumorigenesis (Baker et al., 1990) . Recently, several studies have emerged correlating the presence of p53 mutations with aggressive tumour phenotypes (Martin et al., 1992; Visakorpi et al., 1992) and, most notably, a recently published study by Allred et al. (1993) has shown that p53 mutation, demonstrated by immunohistochemical positivity, is an independent prognostic indicator in multivariate analyses for nodenegative breast cancer.
Leiomyosarcomas of deep soft tissue generally have a very poor prognosis, and this may explain why in our study neither histological grade, clinical stage nor p53/MDM2 mutation predicted overall survival or disease-free survival. A similar study involving a larger group of patients may help resolve whether p53/MDM2 mutation will also predict prognosis in patients with this type of tumour.
Examination of 90 sarcomas showed evidence of mutation of the DCC gene in only a single leiomyosarcoma cell line, SK-UT-1, in which DCC expression as assessed by RNA-PCR analysis was absent. Only 10% of the sarcomas examined showed loss of heterozygosity at the DCC locus, comparing unfavourably with LOH rates of 36% and 23% at the p53 and RBJ loci respectively (Stratton et al., 1990; 1989) , both of which we believe are important in sarcoma development. These results argue against a significant role for mutation of the DCC gene in sarcoma development. 
